---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-353141"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-08-17T10:01:31+00:00"
generated_at: "2026-08-17T10:11:03.919786+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics schedules special meeting for Series C conversion and share issuance

## Summary
- Quince Therapeutics will hold a special meeting to approve issuance of shares upon conversion of 211,301.868 Series C Preferred shares into 10,987,728 common shares.
- Pro forma balance sheet as of June 30, 2026 reflects reclassification of $6.3 million Series C warrant liability to equity.
- The share issuance may exceed 20% of outstanding common stock and could result in change of control under Nasdaq Listing Rule 5635(b).
- Company filed unaudited pro forma condensed consolidated financial information with the SEC on August 17, 2026.

## SEC filing metadata
- accession: 0001193125-26-353141
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-08-17T10:01:31+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526353141/0001193125-26-353141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526353141/d379347d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-353141
- JSON: https://secwatch.observer/filing/0001193125-26-353141.json
- Plain text: https://secwatch.observer/filing/0001193125-26-353141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.